High-molecular-weight and total adiponectin levels and incident symptomatic peripheral artery disease in women: A prospective investigation

Circulation

Volumn 124, Issue 21, 2011, Pages 2303-2311

  Ho, Deborah Y ^a,b   Cook, Nancy R ^b   Britton, Kathryn A ^b   Kim, Eunjung ^b   Creager, Mark A ^b   Ridker, Paul M ^b   Pradhan, Aruna D ^b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BOSTON MEDICAL CENTER   (United States)

Author keywords

adiponectin; biomarker; epidemiology; peripheral artery disease; women

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; HEMOGLOBIN A1C; INTERCELLULAR ADHESION MOLECULE 1; LEPTIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HORMONAL THERAPY; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MOLECULAR WEIGHT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

ADIPONECTIN; AGED; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INTERCELLULAR ADHESION MOLECULE-1; LEPTIN; LONGITUDINAL STUDIES; MOLECULAR WEIGHT; PERIPHERAL ARTERIAL DISEASE; PROSPECTIVE STUDIES;

EID: 81855221753     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.045187     Document Type: Article

References (50)

1. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, Hara K, Hada Y, Vasseur F, Froguel P, Kimura S, Nagai R, Kadowaki T. Impaired multimerization of human adiponectin mutants associated with diabetes. J Biol Chem. 2003;278:40352-40363.
2. Goldstein BJ, Scalia RG, Ma XL. Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med. 2009;6:27-35.
3. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocytesecreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001; 7:947-953. (Pubitemid 32756433)
4. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930-1935. (Pubitemid 32472900)
5. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009;302: 179-188.
6. Zhu N, Pankow JS, Ballantyne CM, Couper D, Hoogeveen RC, Pereira M, Duncan BB, Schmidt MI. High-molecular-weight adiponectin and the risk of type 2 diabetes in the ARIC study. J Clin Endocrinol Metab. 2010;95:5097-5104.
7. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, Ohashi K, Sakai N, Shimomura I, Kobayashi H, Terasaka N, Inaba T, Funahashi T, Matsuzawa Y. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2002;106:2767-2770. (Pubitemid 35396973)
8. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y. Adipocytederived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001;103:1057-1063. (Pubitemid 32200177)
9. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, Yano W, Froguel P, Nagai R, Kimura S, Kadowaki T, Noda T. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem. 2002;277: 25863-25866. (Pubitemid 34967064)
10. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730-1737. (Pubitemid 38489895)
11. Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM, Danesh J, Whincup PH. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation. 2006;114:623-629. (Pubitemid 44252303)
12. Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol. 2007;165:164-174. (Pubitemid 46096378)
13. Pilz S, Maerz W, Weihrauch G, Sargsyan K, Almer G. Adiponectin serum concentrations in men with coronary artery disease: the LUdwigshafen RIsk and Cardiovascular Health (LURIC) study. Clin Chim Acta. 2006; 364:251-255. (Pubitemid 43120651)
14. Wannamethee SG, Whincup PH, Lennon L, Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med. 2007;167: 1510-1517. (Pubitemid 47124181)
15. Lawlor DA, Davey Smith G, Ebrahim S. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab. 2005;90: 5677-5683. (Pubitemid 41415475)
16. Kizer JR, Barzilay JI, Kuller LH, Gottdiener JS. Adiponectin and risk of coronary heart disease in older men and women. J Clin Endocrinol Metab. 2008;93:3357-3364.
17. Sattar N, Watt P, Cherry L, Ebrahim S. High molecular weight adiponectin is not associated with incident coronary heart disease in older women: a nested prospective case-control study. J Clin Endocrinol Metab. 2008;93:1846-1849. (Pubitemid 351656528)
18. Ogorodnikova AD, Wassertheil-Smoller S, Mancuso P, Sowers MR, Rajpathak SN, Allison MA, Baird AE, Rodriguez B, Wildman RP. Highmolecular-weight adiponectin and incident ischemic stroke in postmenopausal women: a Women's Health Initiative Study. Stroke. 2010;41: 1376-1381.
19. Dekker JM, Funahashi T, Nijpels G, Pilz S, Stehouwer CD, Snijder MB, Bouter LM, Matsuzawa Y, Shimomura I, Heine RJ. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab. 2008;93:1489-1496. (Pubitemid 351519753)
20. Iwashima Y, Horio T, Suzuki Y, Kihara S, Rakugi H, Kangawa K, Funahashi T, Ogihara T, Kawano Y. Adiponectin and inflammatory markers in peripheral arterial occlusive disease. Atherosclerosis. 2006; 188:384-390. (Pubitemid 44301128)
21. Golledge J, Leicht A, Crowther RG, Clancy P, Spinks WL, Quigley F. Association of obesity and metabolic syndrome with the severity and outcome of intermittent claudication. J Vasc Surg. 2007;45:40-46. (Pubitemid 46043539)
22. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979. (Pubitemid 27152782)
23. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294:56-65. (Pubitemid 41002839)
24. Leng GC, Fowkes FGR. The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose questionnaire for use in epidemiological surveys. J Clin Epidemiol. 1992;45:1101-1109.
25. Ridker PM, Chasman DI, Zee RY, Parker A, Rose L, Cook NR, Buring JE; Women's Genome Health Study Working Group. Rationale, design, and methodology of the Women's Genome Health Study: a genome-wide association study of more than 25 000 initially healthy American women. Clin Chem. 2008;54:249-255. (Pubitemid 351302617)
26. Boden G, Chen X, Mozzoli M, Ryan I. Effect of fasting on serum leptin in normal human subjects. J Clin Endocrinol Metab. 1996;81: 3419-3423. (Pubitemid 26296227)
27. Gavrila A, Chan JL, Yiannakouris N, Kontogianni M, Miller LC, Orlova C, Mantzoros CS. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: crosssectional and interventional studies. J Clin Endocrinol Metab. 2003; 88:4823-4831. (Pubitemid 37357532)
28. Pradhan AD, Shrivastava S, Cook NR, Rifai N, Creager MA, Ridker PM. Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk. Circulation. 2008;117:823-831. (Pubitemid 351640684)
29. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, Imai Y, Nagai R, Kadowaki T. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care. 2006;29: 1357-1362. (Pubitemid 44125935)
30. Heidemann C, Sun Q, van Dam RM. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med. 2008;149:307-316.
31. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 2005;112:1756-1762. (Pubitemid 41372115)
32. Urbonaviciene G, Frystyk J, Flyvbjerg A, Henneberg EW, Lindholt JS. Association of serum adiponectin with risk for cardiovascular events in patients with peripheral arterial disease. Atherosclerosis. 2010;210: 619-624.
33. Dieplinger B, Haltmayer M, Poelz W, Mueller T. Value of adiponectin as predictor of 5-year all-cause mortality in patients with symptomatic peripheral arterial disease: results from the Linz Peripheral Arterial Disease (LIPAD) study. Clin Chim Acta. 2009;408:87-91.
34. Komai H, Shibata R, Juri M, Matsushita K, Ouchi N, Murohara T. Plasma adiponectin as a predictive factor of survival after a bypass operation for peripheral arterial disease. J Vasc Surg. 2009;50:95-99.
35. Pernow B, Zetterquist S. Metabolic evaluation of the leg blood flow in claudicating patients with arterial obstructions at different levels. Scand J Clin Lab Invest. 1968;21:277-287.
36. Gardner AW, Skinner JS, Cantwell BW, Smith LK. Prediction of claudication pain from clinical measurements obtained at rest. Med Sci Sports Exerc. 1992;24:163-170.
37. Regensteiner JG, Hargarten ME, Rutherford RB, Hiatt WR. Functional benefits of peripheral vascular bypass surgery for patients with intermittent claudication. Angiology. 1993;44:1-10. (Pubitemid 23033195)
38. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. N Engl J Med. 2002;347:1941-1951.
39. Brass EP, Hiatt WR. Acquired skeletal muscle metabolic myopathy in atherosclerotic peripheral arterial disease. Vasc Med. 2000;5:55-59. (Pubitemid 30143363)
40. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423:762-769. (Pubitemid 36735700)
41. Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, Yamaguchi M, Namiki S, Nakayama R, Tabata M, Ogata H, Kubota N, Takamoto I, Hayashi YK, Yamauchi N, Waki H, Fukayama M, Nishino I, Tokuyama K, Ueki K, Oike Y, Ishii S, Hirose K, Shimizu T, Touhara K, Kadowaki T. Adiponectin and AdipoR1 regulate PGC-1[agr] and mitochondria by Ca2+and AMPK/SIRT1. Nature. 2010;464: 1313-1319.
42. Merki-Feld GS, Imthurn B, Rosselli M, Spanaus K. Serum concentrations of high-molecular weight adiponectin and their association with sex steroids in premenopausal women. Metabolism. 2011;60:180-185.
43. Xu A, Chan KW, Hoo RLC, Wang Y, Tan KC, Zhang J, Chen B, Lam MC, Tse C, Cooper GJ, Lam KS. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem. 2005;280:18073-18080. (Pubitemid 41389052)
44. Laughlin GA, Barrett-Connor E, May S. Sex-specific association of the androgen to oestrogen ratio with adipocytokine levels in older adults: the Rancho Bernardo Study. Clin Endocrinol (Oxf). 2006;65: 506-513. (Pubitemid 44414275)
45. Dieter RS, Biring T, Tomasson J, Gudjonsson T, Brown RL, Vitcenda M, Einerson J, Tanke TE, McBride PE. Classic intermittent claudication is an uncommon manifestation of lower extremity peripheral arterial disease in hospitalized patients with coronary artery disease. Angiology. 2004;55: 625-628. (Pubitemid 39551958)
46. McGrae McDermott M, Mehta S, Greenland P. Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease. Arch Intern Med. 1999;159:387-392. (Pubitemid 29091628)
47. Vavra AK, Kibbe MR. Women and peripheral arterial disease. Women's Health. 2009;5:669-683.
48. Aboyans V, Criqui MH, McClelland RL, Allison MA, McDermott MM, Goff DC Jr, Manolio TA. Intrinsic contribution of gender and ethnicity to normal ankle-brachial index values: the Multi-Ethnic Study of Atherosclerosis (MESA). J Vasc Surg. 2007;45:319-327. (Pubitemid 46149994)
49. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease: the San Luis Valley Diabetes Study. Circulation. 1995;91:1472-1479.
50. Hui X, Lam KSL, Vanhoutte PM, Xu A. Adiponectin and cardiovascular health: an update [published online ahead of print]. Br J Pharmacol. 2011. doi:10.1111/j.1476-5381.2011.01395.x.